{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,31]],"date-time":"2026-07-31T03:33:07Z","timestamp":1785468787816,"version":"3.56.0"},"reference-count":200,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2026,5,15]],"date-time":"2026-05-15T00:00:00Z","timestamp":1778803200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100006769","name":"Russian Science Foundation","doi-asserted-by":"publisher","award":["\u211625-25-01166"],"award-info":[{"award-number":["\u211625-25-01166"]}],"id":[{"id":"10.13039\/501100006769","id-type":"DOI","asserted-by":"publisher"}]},{"award":["\u211625-25-01166"],"award-info":[{"award-number":["\u211625-25-01166"]}],"id":[{"id":"https:\/\/ror.org\/03y2gwe85","id-type":"ROR","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Metabolic dysfunction-associated steatotic liver disease (MASLD) is a widespread condition with a complex pathogenesis. Cell-based models are important tools for studying the mechanisms underlying its development and progression. The aim of this review is to analyze the HepaRG, Huh-7, immortalized human hepatocyte (IHH), and primary human hepatocyte (PHH) cell lines for modeling and studying MASLD. HepaRG represents the most metabolically competent immortalized hepatocyte model with preserved biotransformation activity and a physiological bioenergetic response to lipid loading, making it valuable for pharmacological and toxicological studies. Huh-7 is distinguished by its accessibility and suitability for studying steatosis, lipotoxicity, insulin resistance, and paracrine mechanisms of fibrogenesis; however, its use is limited by its tumor origin, impaired carbohydrate metabolism, and low activity of xenobiotic-metabolizing enzymes. The IHH model occupies an intermediate position because of its non-tumor origin and is of interest for studies of senescence, epigenetic regulation, and signaling pathways involved in steatosis, although interpretation of results requires consideration of immortalization-related effects and specific metabolic limitations. PHH remains the most physiologically relevant platform for MASLD modeling, particularly in three-dimensional (3D) and microphysiological formats; however, its use is limited by high cost, interindividual variability, and the limited duration of the differentiated phenotype. Increasing model complexity\u2014from two-dimensional (2D) monocultures to co-cultures, spheroids, and organ-on-chip systems\u2014enhances physiological relevance and enables reproduction not only of steatosis but also of the inflammatory and fibrogenic components of MASLD progression, yet it reduces reproducibility and complicates standardization. Overall, none of the existing models is universal, and the optimal strategy is to select models according to the specific research question. A key direction for future research is the standardization of steatosis induction protocols and the unification of criteria for evaluating results.<\/jats:p>","DOI":"10.3390\/ijms27104453","type":"journal-article","created":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:40:31Z","timestamp":1779115231000},"page":"4453","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Hepatocyte Models for Metabolic Dysfunction-Associated Steatotic Liver Disease: A Comparative Analysis of Non-HepG2 Cell Models"],"prefix":"10.3390","volume":"27","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0676-7558","authenticated-orcid":false,"given":"Anna","family":"Kotlyarova","sequence":"first","affiliation":[{"name":"Department of Pharmacy Management and Economics, Ryazan State Medical University, 390026 Ryazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7083-2692","authenticated-orcid":false,"given":"Stanislav","family":"Kotlyarov","sequence":"additional","affiliation":[{"name":"Department of Nursing, Ryazan State Medical University, 390026 Ryazan, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2026,5,15]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"847","DOI":"10.1186\/s40001-025-03151-9","article-title":"Stratified Cardiovascular Risk in Patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Impact of Varying Metabolic Risk Factor Burden","volume":"30","author":"Elsabaawy","year":"2025","journal-title":"Eur. J. Med. Res."},{"key":"ref_2","doi-asserted-by":"crossref","unstructured":"Dua, A., Kumari, R., Singh, M., Kumar, R., Pradeep, S., Ojesina, A.I., and Kumar, R. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): The Interplay of Gut Microbiome, Insulin Resistance, and Diabetes. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1618275"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"e70132","DOI":"10.1002\/edm2.70132","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): Mechanisms, Clinical Implications and Therapeutic Advances","volume":"8","author":"Miller","year":"2025","journal-title":"Endocrinol. Diabetes Metab."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Mustafa, A., Kite, C., Lagojda, L., Dallaway, A., Chatha, K.K., Than, N.N., Kassi, E., Kyrou, I., and Randeva, H.S. (2025). Cardiovascular Disease in the Context of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A Comprehensive Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms262311275"},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Mastoridou, E.M., Goussia, A.C., Kataki, A., Koniaris, E., Glantzounis, G.K., Papoudou-Bai, A., Kanavaros, P., and Charchanti, A.V. (2026). The Interplay Between Cellular Senescence and Lipid Metabolism in the Progression of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27021066"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"100526","DOI":"10.1016\/j.clinme.2025.100526","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"25","author":"Hsu","year":"2025","journal-title":"Clin. Med."},{"key":"ref_7","doi-asserted-by":"crossref","unstructured":"Lake-Bakaar, G. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): New Perspectives on an Evolving Epidemic. J. Clin. Med., 14.","DOI":"10.20944\/preprints202510.2378.v1"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1335","DOI":"10.1097\/HEP.0000000000000004","article-title":"The Global Epidemiology of Nonalcoholic Fatty Liver Disease (NAFLD) and Nonalcoholic Steatohepatitis (NASH): A Systematic Review","volume":"77","author":"Younossi","year":"2023","journal-title":"Hepatology"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"964","DOI":"10.4093\/dmj.2025.0644","article-title":"Hepatic Insulin Resistance and Steatosis in Metabolic Dysfunction-Associated Steatotic Liver Disease: New Insights into Mechanisms and Clinical Implications","volume":"49","author":"Truong","year":"2025","journal-title":"Diabetes Metab. J."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1016\/S2213-8587(22)00003-1","article-title":"A Global View of the Interplay between Non-Alcoholic Fatty Liver Disease and Diabetes","volume":"10","author":"Stefan","year":"2022","journal-title":"Lancet Diabetes Endocrinol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2138","DOI":"10.1136\/gutjnl-2023-330110","article-title":"Global Prevalence of Non-Alcoholic Fatty Liver Disease in Type 2 Diabetes Mellitus: An Updated Systematic Review and Meta-Analysis","volume":"72","author":"Ang","year":"2023","journal-title":"Gut"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e13564","DOI":"10.1111\/1753-0407.13564","article-title":"Prevalence of Nonalcoholic Fatty Liver Disease and Liver Cirrhosis in Chinese Adults with Type 2 Diabetes Mellitus","volume":"16","author":"Han","year":"2024","journal-title":"J. Diabetes"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Beyazal Polat, H., Beyazal, M., Arpa, M., K\u0131z\u0131lkaya, B., Ayaz, T., G\u00fcndo\u011fdu, \u00d6.L., Konur, K., Polat, Z., Beyazal \u00c7eliker, F., and Atasoy, H. (2025). Exploring the Prevalence and Risk Factors of MASLD in Patients with Newly Diagnosed Diabetes Mellitus: A Comprehensive Investigation. J. Clin. Med., 14.","DOI":"10.3390\/jcm14103513"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"60","DOI":"10.1186\/s13098-020-00570-y","article-title":"NAFLD as a Continuum: From Obesity to Metabolic Syndrome and Diabetes","volume":"12","author":"Valerio","year":"2020","journal-title":"Diabetol. Metab. Syndr."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"421","DOI":"10.4103\/ijem.IJEM_585_17","article-title":"Nonalcoholic Fatty Liver Disease and Type 2 Diabetes Mellitus","volume":"22","author":"Dharmalingam","year":"2018","journal-title":"Indian J. Endocrinol. Metab."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1016\/j.cmet.2024.04.006","article-title":"Hepatic Selective Insulin Resistance at the Intersection of Insulin Signaling and Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"36","author":"Bo","year":"2024","journal-title":"Cell Metab."},{"key":"ref_17","unstructured":"Girish, V., and John, S. (2025). Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD). StatPearls [Internet], StatPearls Publishing."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1186\/s12933-024-02434-5","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Risk: A Comprehensive Review","volume":"23","author":"Zheng","year":"2024","journal-title":"Cardiovasc. Diabetol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1097\/HEP.0000000000000520","article-title":"A Multisociety Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"78","author":"Rinella","year":"2023","journal-title":"Hepatology"},{"key":"ref_20","first-page":"815","article-title":"Mechanism of Metabolic Dysfunction-Associated Steatotic Liver Disease: Important Role of Lipid Metabolism","volume":"12","author":"Feng","year":"2024","journal-title":"J. Clin. Transl. Hepatol."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Termite, F., Archilei, S., D\u2019Ambrosio, F., Petrucci, L., Viceconti, N., Iaccarino, R., Liguori, A., Gasbarrini, A., and Miele, L. (2025). Gut Microbiota at the Crossroad of Hepatic Oxidative Stress and MASLD. Antioxidants, 14.","DOI":"10.3390\/antiox14010056"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1097\/MCG.0b013e31824587e0","article-title":"Nonalcoholic Fatty Liver Disease: Multimodal Treatment Options for a Pathogenetically Multiple-Hit Disease","volume":"46","author":"Polyzos","year":"2012","journal-title":"J. Clin. Gastroenterol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/hep.31518","article-title":"Multiple Parallel Hits Hypothesis in Nonalcoholic Fatty Liver Disease: Revisited After a Decade","volume":"73","author":"Tilg","year":"2021","journal-title":"Hepatology"},{"key":"ref_24","doi-asserted-by":"crossref","unstructured":"Sandireddy, R., Sakthivel, S., Gupta, P., Behari, J., Tripathi, M., and Singh, B.K. (2024). Systemic Impacts of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) and Metabolic Dysfunction-Associated Steatohepatitis (MASH) on Heart, Muscle, and Kidney Related Diseases. Front. Cell Dev. Biol., 12.","DOI":"10.3389\/fcell.2024.1433857"},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"100195","DOI":"10.1016\/j.iliver.2025.100195","article-title":"Pathogenesis of Metabolic Dysfunction-Associated Steatotic Liver Disease and Donor Liver Damage","volume":"4","author":"Gou","year":"2025","journal-title":"ILIVER"},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"E93","DOI":"10.1097\/HEP.0000000000000696","article-title":"Reply: A Multi-Society Delphi Consensus Statement on New Fatty Liver Disease Nomenclature","volume":"79","author":"Lazarus","year":"2024","journal-title":"Hepatology"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"197","DOI":"10.7570\/jomes23052","article-title":"Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD): A State-of-the-Art Review","volume":"32","author":"Chan","year":"2023","journal-title":"J. Obes. Metab. Syndr."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"100485","DOI":"10.1016\/j.jlr.2023.100485","article-title":"From NAFLD to MASLD: Updated Naming and Diagnosis Criteria for Fatty Liver Disease","volume":"65","author":"Rinella","year":"2023","journal-title":"J. Lipid Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1007\/s10620-016-4143-0","article-title":"Global Epidemiology of Non-Alcoholic Fatty Liver Disease and Perspectives on US Minority Populations","volume":"61","author":"Sherif","year":"2016","journal-title":"Dig. Dis. Sci."},{"key":"ref_30","first-page":"e50159","article-title":"A Comprehensive Review on Non-Alcoholic Fatty Liver Disease","volume":"15","author":"Sahu","year":"2023","journal-title":"Cureus"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"846","DOI":"10.4254\/wjh.v7.i6.846","article-title":"Non-Alcoholic Fatty Liver Disease: The Diagnosis and Management","volume":"7","year":"2015","journal-title":"World J. Hepatol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"514","DOI":"10.21037\/hbsn.2019.11.28","article-title":"Nonalcoholic Fatty Liver Disease and Type 2 Diabetes: A Burgeoning Problem with Unclear Solutions","volume":"9","author":"Lazo","year":"2020","journal-title":"Hepatobiliary Surg. Nutr."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1038\/s42255-024-01043-6","article-title":"An Unbiased Ranking of Murine Dietary Models Based on Their Proximity to Human Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"6","author":"Vacca","year":"2024","journal-title":"Nat. Metab."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Fu, Y., Hua, Y., Alam, N., and Liu, E. (2024). Progress in the Study of Animal Models of Metabolic Dysfunction-Associated Steatotic Liver Disease. Nutrients, 16.","DOI":"10.3390\/nu16183120"},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"304","DOI":"10.4254\/wjh.v14.i2.304","article-title":"Rodent Models and Metabolomics in Non-Alcoholic Fatty Liver Disease: What Can We Learn?","volume":"14","author":"Marrachelli","year":"2022","journal-title":"World J. Hepatol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"6506","DOI":"10.1038\/s41467-024-50660-y","article-title":"A Male Mouse Model for Metabolic Dysfunction-Associated Steatotic Liver Disease and Hepatocellular Carcinoma","volume":"15","author":"Jeong","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_37","doi-asserted-by":"crossref","unstructured":"Hernandez, R., Garcia-Rodriguez, N.S., Arriaga, M.A., Perez, R., Bala, A.A., Leandro, A.C., Diego, V.P., Almeida, M., Parsons, J.G., and Manusov, E.G. (2025). The Hepatocellular Model of Fatty Liver Disease: From Current Imaging Diagnostics to Innovative Proteomics Technologies. Front. Med., 12.","DOI":"10.3389\/fmed.2025.1513598"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"7347068","DOI":"10.1155\/2020\/7347068","article-title":"Mouse Models of Nonalcoholic Steatohepatitis: Head-to-Head Comparison of Dietary Models and Impact on Inflammation and Animal Welfare","volume":"2020","author":"Kroh","year":"2020","journal-title":"Gastroenterol. Res. Pract."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1007\/s00204-020-02939-4","article-title":"Cross-Species Analysis of Hepatic Cytochrome P450 and Transport Protein Expression","volume":"95","author":"Hammer","year":"2021","journal-title":"Arch. Toxicol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1124\/dmd.105.009035","article-title":"Comparison of Mouse and Rat Cytochrome P450-Mediated Metabolism in Liver and Intestine","volume":"34","author":"Martignoni","year":"2006","journal-title":"Drug Metab. Dispos. Biol. Fate Chem."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"2686","DOI":"10.1021\/acs.jproteome.5b00213","article-title":"A Comparison of the Mouse and Human Lipoproteome: Suitability of the Mouse Model for Studies of Human Lipoproteins","volume":"14","author":"Gordon","year":"2015","journal-title":"J. Proteome Res."},{"key":"ref_42","first-page":"149","article-title":"High-Density Lipoprotein Metabolism and Reverse Cholesterol Transport: Strategies for Raising HDL Cholesterol","volume":"18","author":"Trajkovska","year":"2017","journal-title":"Anatol. J. Cardiol."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"2058","DOI":"10.1194\/jlr.R001610","article-title":"The HDL Hypothesis: Does High-Density Lipoprotein Protect from Atherosclerosis?","volume":"51","author":"Vergeer","year":"2010","journal-title":"J. Lipid Res."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"51","DOI":"10.1194\/jlr.M019927","article-title":"Plasma Lipid Profiling across Species for the Identification of Optimal Animal Models of Human Dyslipidemia","volume":"53","author":"Yin","year":"2012","journal-title":"J. Lipid Res."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"656","DOI":"10.1002\/hep.31052","article-title":"Insights From Liver-Humanized Mice on Cholesterol Lipoprotein Metabolism and LXR-Agonist Pharmacodynamics in Humans","volume":"72","author":"Minniti","year":"2020","journal-title":"Hepatology"},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1111\/aor.14503","article-title":"FDA Modernization Act 2.0 Allows for Alternatives to Animal Testing","volume":"47","author":"Han","year":"2023","journal-title":"Artif. Organs"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1188","DOI":"10.1021\/acsptsci.4c00661","article-title":"The 3C (Cell Culture, Computer Simulation, Clinical Trial) Solution for Optimizing the 3R (Replace, Reduction, Refine) Framework during Preclinical Research Involving Laboratory Animals","volume":"8","author":"Roy","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_48","doi-asserted-by":"crossref","unstructured":"Hubrecht, R.C., and Carter, E. (2019). The 3Rs and Humane Experimental Technique: Implementing Change. Animals, 9.","DOI":"10.3390\/ani9100754"},{"key":"ref_49","first-page":"120","article-title":"Russell and Burch\u2019s 3Rs Then and Now: The Need for Clarity in Definition and Purpose","volume":"54","author":"Tannenbaum","year":"2015","journal-title":"J. Am. Assoc. Lab. Anim. Sci. JAALAS"},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Liu, J., Zai, X., Tian, X., Li, J., Yan, S., and Wang, T. (2025). Practical Implementation and Impact of the 4R Principles in Ethnopharmacology: Pursuing a More Humane Approach to Research. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1543316"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"103549","DOI":"10.1016\/j.isci.2021.103549","article-title":"In Vitro Models for Non-Alcoholic Fatty Liver Disease: Emerging Platforms and Their Applications","volume":"25","author":"Ramos","year":"2021","journal-title":"iScience"},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1016\/j.bbalip.2017.11.006","article-title":"Cell Culture Models of Fatty Acid Overload: Problems and Solutions","volume":"1863","author":"Alsabeeh","year":"2018","journal-title":"Biochim. Biophys. Acta"},{"key":"ref_53","doi-asserted-by":"crossref","unstructured":"Gatzios, A., Rombaut, M., Buyl, K., De Kock, J., Rodrigues, R.M., Rogiers, V., Vanhaecke, T., and Boeckmans, J. (2022). From NAFLD to MAFLD: Aligning Translational In Vitro Research to Clinical Insights. Biomedicines, 10.","DOI":"10.3390\/biomedicines10010161"},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.cotox.2019.03.001","article-title":"Human in Vitro Models of Nonalcoholic Fatty Liver Disease","volume":"16","author":"Sturla","year":"2019","journal-title":"Curr. Opin. Toxicol."},{"key":"ref_55","first-page":"95","article-title":"Quantification and Mechanisms of Oleic Acid-Induced Steatosis in HepG2 Cells","volume":"2","author":"Cui","year":"2010","journal-title":"Am. J. Transl. Res."},{"key":"ref_56","first-page":"183","article-title":"In Vitro Treatment of HepG2 Cells with Saturated Fatty Acids Reproduces Mitochondrial Dysfunction Found in Nonalcoholic Steatohepatitis","volume":"8","year":"2015","journal-title":"Dis. Model. Mech."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1016\/j.cbi.2006.11.004","article-title":"A Human Hepatocellular in Vitro Model to Investigate Steatosis","volume":"165","author":"Donato","year":"2007","journal-title":"Chem. Biol. Interact."},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"17019","DOI":"10.1038\/s41598-023-44198-0","article-title":"A Model of Hepatic Steatosis with Declined Viability and Function in a Liver-Organ-on-a-Chip","volume":"13","author":"Wiriyakulsit","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_59","doi-asserted-by":"crossref","unstructured":"Pingitore, P., Sasidharan, K., Ekstrand, M., Prill, S., Lind\u00e9n, D., and Romeo, S. (2019). Human Multilineage 3D Spheroids as a Model of Liver Steatosis and Fibrosis. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20071629"},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"25094","DOI":"10.1021\/acsomega.4c02433","article-title":"In Vitro Nonalcoholic Fatty Liver Disease Model Elucidating the Effect of Immune Environment on Disease Progression and Alleviation","volume":"9","author":"Kim","year":"2024","journal-title":"ACS Omega"},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"383","DOI":"10.1016\/j.ajg.2025.09.002","article-title":"Investigating the Process of Apoptosis in HepG2 Cells Treated with Palmitate, Oleate, and Palmitate\/Oleate Combination","volume":"26","author":"Torabi","year":"2025","journal-title":"Arab J. Gastroenterol."},{"key":"ref_62","doi-asserted-by":"crossref","unstructured":"Rafiei, H., Yeung, M., Kowalski, S., Krystal, G., and Elisia, I. (2023). Development of a Novel Human Triculture Model of Non-Alcoholic Fatty Liver Disease and Identification of Berberine as Ameliorating Steatosis, Oxidative Stress and Fibrosis. Front. Pharmacol., 14.","DOI":"10.3389\/fphar.2023.1234300"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1038\/s42003-023-04710-8","article-title":"Integrated-Gut-Liver-on-a-Chip Platform as an in Vitro Human Model of Non-Alcoholic Fatty Liver Disease","volume":"6","author":"Yang","year":"2023","journal-title":"Commun. Biol."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1186\/s10020-024-00945-1","article-title":"Exosomes Derived from Apical Papilla Stem Cells Improve NASH by Regulating Fatty Acid Metabolism and Reducing Inflammation","volume":"30","author":"Nie","year":"2024","journal-title":"Mol. Med."},{"key":"ref_65","first-page":"e66810","article-title":"In Vitro Modeling of Fat Deposition in Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"209","author":"Bao","year":"2024","journal-title":"J. Vis. Exp."},{"key":"ref_66","doi-asserted-by":"crossref","unstructured":"Kotlyarova, A., Iskrina, A., and Kotlyarov, S. (2026). The HepG2 Cell Line as a Model for Studying Metabolic Dysfunction-Associated Steatotic Liver Disease. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27083399"},{"key":"ref_67","doi-asserted-by":"crossref","unstructured":"Soret, P.-A., Magusto, J., Housset, C., and Gautheron, J. (2021). In Vitro and In Vivo Models of Non-Alcoholic Fatty Liver Disease: A Critical Appraisal. J. Clin. Med., 10.","DOI":"10.3390\/jcm10010036"},{"key":"ref_68","doi-asserted-by":"crossref","unstructured":"Pelech\u00e1, M., Villanueva-B\u00e1denas, E., Timor-L\u00f3pez, E., Donato, M.T., and Tolosa, L. (2022). Cell Models and Omics Techniques for the Study of Nonalcoholic Fatty Liver Disease: Focusing on Stem Cell-Derived Cell Models. Antioxidants, 11.","DOI":"10.3390\/antiox11010086"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"202","DOI":"10.1016\/j.jhep.2020.03.039","article-title":"A New Definition for Metabolic Dysfunction-Associated Fatty Liver Disease: An International Expert Consensus Statement","volume":"73","author":"Eslam","year":"2020","journal-title":"J. Hepatol."},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1111\/bcpt.12631","article-title":"Human Hepatic HepaRG Cells Maintain an Organotypic Phenotype with High Intrinsic CYP450 Activity\/Metabolism and Significantly Outperform Standard HepG2\/C3A Cells for Pharmaceutical and Therapeutic Applications","volume":"120","author":"Nelson","year":"2017","journal-title":"Basic Clin. Pharmacol. Toxicol."},{"key":"ref_71","doi-asserted-by":"crossref","unstructured":"Obara, C., Iizaka, Y., Mine, A., Anzai, Y., Tada, M., and Yamaguchi, S. (2025). Development of a CYP2D6-Enhanced HepaRG Cell Model with Improved CYP2D6 Metabolic Capacity. PLoS ONE, 20.","DOI":"10.1371\/journal.pone.0339559"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1080\/26896583.2024.2331956","article-title":"Application of HepaRG Cells for Genotoxicity Assessment: A Review","volume":"42","author":"Guo","year":"2024","journal-title":"J. Environ. Sci. Health Part C Toxicol. Carcinog."},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"15655","DOI":"10.1073\/pnas.232137699","article-title":"Infection of a Human Hepatoma Cell Line by Hepatitis B Virus","volume":"99","author":"Gripon","year":"2002","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1007\/s12079-018-0456-4","article-title":"Oxygen Drives Hepatocyte Differentiation and Phenotype Stability in Liver Cell Lines","volume":"12","author":"Adam","year":"2018","journal-title":"J. Cell Commun. Signal."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"144","DOI":"10.1038\/s41426-018-0143-9","article-title":"Optimized HepaRG Is a Suitable Cell Source to Generate the Human Liver Chimeric Mouse Model for the Chronic Hepatitis B Virus Infection","volume":"7","author":"Yuan","year":"2018","journal-title":"Emerg. Microbes Infect."},{"key":"ref_76","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1002\/hep.24132","article-title":"HepaRG cells: A human model to study mechanisms of acetaminophen hepatotoxicity","volume":"53","author":"McGill","year":"2011","journal-title":"Hepatology"},{"key":"ref_77","doi-asserted-by":"crossref","unstructured":"Tascher, G., Burban, A., Camus, S., Plumel, M., Chanon, S., Guevel, R.L., Shevchenko, V., Dorsselaer, A.V., Lefai, E., and Guguen-Guillouzo, C. (2019). In-Depth Proteome Analysis Highlights HepaRG Cells as a Versatile Cell System Surrogate for Primary Human Hepatocytes. Cells, 8.","DOI":"10.3390\/cells8020192"},{"key":"ref_78","doi-asserted-by":"crossref","unstructured":"Deng, J., Wei, W., Chen, Z., Lin, B., Zhao, W., Luo, Y., and Zhang, X. (2019). Engineered Liver-on-a-Chip Platform to Mimic Liver Functions and Its Biomedical Applications: A Review. Micromachines, 10.","DOI":"10.3390\/mi10100676"},{"key":"ref_79","doi-asserted-by":"crossref","unstructured":"Kammerer, S. (2021). Three-Dimensional Liver Culture Systems to Maintain Primary Hepatic Properties for Toxicological Analysis In Vitro. Int. J. Mol. Sci., 22.","DOI":"10.3390\/ijms221910214"},{"key":"ref_80","doi-asserted-by":"crossref","unstructured":"Xu, Q. (2021). Human Three-Dimensional Hepatic Models: Cell Type Variety and Corresponding Applications. Front. Bioeng. Biotechnol., 9.","DOI":"10.3389\/fbioe.2021.730008"},{"key":"ref_81","doi-asserted-by":"crossref","first-page":"e2007425","DOI":"10.1002\/smll.202007425","article-title":"Bioengineered Multicellular Liver Microtissues for Modeling Advanced Hepatic Fibrosis Driven through Non-Alcoholic Fatty Liver Disease","volume":"17","author":"Cho","year":"2021","journal-title":"Small Weinh. Bergstr. Ger."},{"key":"ref_82","doi-asserted-by":"crossref","unstructured":"Jochum, K., St\u00e4dele, V., and Marx-Stoelting, P. (2025). Changes in Cultivation Parameters Impact Cytochrome P450 Gene Transcription in HepaRG Cells: Implications for in Vitro Toxicological Assessments. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1690384"},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"18","DOI":"10.3892\/ijmm.2023.5342","article-title":"Comparison of HepaRG and HepG2 Cell Lines to Model Mitochondrial Respiratory Adaptations in Non-Alcoholic Fatty Liver Disease","volume":"53","author":"Maseko","year":"2023","journal-title":"Int. J. Mol. Med."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"e13532","DOI":"10.14814\/phy2.13532","article-title":"In Vitro Cellular Models of Human Hepatic Fatty Acid Metabolism: Differences between Huh7 and HepG2 Cell Lines in Human and Fetal Bovine Culturing Serum","volume":"5","author":"Gunn","year":"2017","journal-title":"Physiol. Rep."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"100010","DOI":"10.1016\/j.ooc.2021.100010","article-title":"In Vitro Nonalcoholic Fatty Liver Disease Model with Cyclo-Olefin-Polymer-Based Microphysiological Systems","volume":"3","author":"Wen","year":"2021","journal-title":"Organs-A-Chip"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"105728","DOI":"10.1016\/j.tiv.2023.105728","article-title":"3D Multi-Cell-Type Liver Organoids: A New Model of Non-Alcoholic Fatty Liver Disease for Drug Safety Assessments","volume":"94","author":"Bronsard","year":"2024","journal-title":"Toxicol. In Vitro"},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"105184","DOI":"10.1016\/j.ebiom.2024.105184","article-title":"Soluble CD46 as a Diagnostic Marker of Hepatic Steatosis","volume":"104","author":"Bitterer","year":"2024","journal-title":"eBioMedicine"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"3867","DOI":"10.7150\/ijbs.108268","article-title":"Polystyrene Nanoplastics Exacerbate HFD-Induced MASLD by Reducing Cathepsin Activity and Triggering Large Vacuole Formation via Impaired Lysosomal Acidification","volume":"21","author":"Ahn","year":"2025","journal-title":"Int. J. Biol. Sci."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1016\/j.taap.2015.12.020","article-title":"A Cellular Model to Study Drug-Induced Liver Injury in Nonalcoholic Fatty Liver Disease: Application to Acetaminophen","volume":"292","author":"Michaut","year":"2016","journal-title":"Toxicol. Appl. Pharmacol."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1096\/fj.14-267393","article-title":"ILr1\u03b2 Production Is Dependent on the Activation of Purinergic Receptors and NLRP3 Pathway in Human Macrophages","volume":"29","author":"Gicquel","year":"2015","journal-title":"FASEB J."},{"key":"ref_91","first-page":"3858","article-title":"Growth of Human Hepatoma Cells Lines with Differentiated Functions in Chemically Defined Medium","volume":"42","author":"Nakabayashi","year":"1982","journal-title":"Cancer Res."},{"key":"ref_92","doi-asserted-by":"crossref","unstructured":"Luis, D.D., Liehr, T., Kankel, S., Weise, A., Pentzold, C., Buhl, E.M., Hardt, K.S., Keller, D.T., Schr\u00f6der-Lange, S.K., and Weiskirchen, R. (2025). Decoding HuH-7: A Comprehensive Genetic and Molecular Portrait of a Widely Used Hepatocellular Carcinoma Model. Front. Cell Dev. Biol., 13.","DOI":"10.3389\/fcell.2025.1648639"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"606","DOI":"10.4236\/jct.2013.42078","article-title":"Huh-7 Human Liver Cancer Cells: A Model System to Understand Hepatocellular Carcinoma and Therapy","volume":"4","author":"Krelle","year":"2013","journal-title":"J. Cancer Ther."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s13577-018-0212-3","article-title":"HuH-7 Reference Genome Profile: Complex Karyotype Composed of Massive Loss of Heterozygosity","volume":"31","author":"Kasai","year":"2018","journal-title":"Hum. Cell"},{"key":"ref_95","doi-asserted-by":"crossref","unstructured":"Sainz, B., Barretto, N., and Uprichard, S.L. (2009). Hepatitis C Virus Infection in Phenotypically Distinct Huh7 Cell Lines. PLoS ONE, 4.","DOI":"10.1371\/journal.pone.0006561"},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Kawamoto, M., Yamaji, T., Saito, K., Shirasago, Y., Satomura, K., Endo, T., Fukasawa, M., Hanada, K., and Osada, N. (2020). Identification of Characteristic Genomic Markers in Human Hepatoma HuH-7 and Huh7.5.1-8 Cell Lines. Front. Genet., 11.","DOI":"10.3389\/fgene.2020.546106"},{"key":"ref_97","doi-asserted-by":"crossref","unstructured":"Zhou, T., C\u00f6mert, C., Zhou, X., Lin, L., Bolund, L., Palmfeldt, J., Tong, G., Luo, Y., and Bross, P. (2021). Energy Metabolism Adaptations and Gene Expression Reprogramming in a Cellular MAFLD model. bioRxiv, bioRxiv:2021.11.08.467719.","DOI":"10.1101\/2021.11.08.467719"},{"key":"ref_98","first-page":"421","article-title":"Bioengineering Scalable and Drug-Responsive in Vitro Human Multicellular Non-Alcoholic Fatty Liver Disease Microtissues Encapsulated in the Liver Extracellular Matrix-Derived Hydrogel","volume":"23","author":"Asadollahi","year":"2024","journal-title":"EXCLI J."},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"560","DOI":"10.1002\/hep.29588","article-title":"Non-Alcoholic Fatty Liver Disease Impairs Expression of the Type II Inositol 1,4,5-Trisphosphate Receptor","volume":"67","author":"Khamphaya","year":"2018","journal-title":"Hepatology"},{"key":"ref_100","doi-asserted-by":"crossref","unstructured":"Takahara, I., Akazawa, Y., Tabuchi, M., Matsuda, K., Miyaaki, H., Kido, Y., Kanda, Y., Taura, N., Ohnita, K., and Takeshima, F. (2017). Toyocamycin Attenuates Free Fatty Acid-Induced Hepatic Steatosis and Apoptosis in Cultured Hepatocytes and Ameliorates Nonalcoholic Fatty Liver Disease in Mice. PLoS ONE, 12, Correction in PLoS ONE. 2020, 15, e0235729. https:\/\/doi.org\/10.1371\/journal.pone.0235729.","DOI":"10.1371\/journal.pone.0235729"},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1016\/j.tiv.2015.07.010","article-title":"The Interplay between Hepatic Stellate Cells and Hepatocytes in an in Vitro Model of NASH","volume":"29","author":"Giraudi","year":"2015","journal-title":"Toxicol. In Vitro"},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3710","DOI":"10.1038\/s41598-017-03389-2","article-title":"Exosomes Derived from Palmitic Acid-Treated Hepatocytes Induce Fibrotic Activation of Hepatic Stellate Cells","volume":"7","author":"Lee","year":"2017","journal-title":"Sci. Rep."},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"G1","DOI":"10.1152\/ajpgi.00193.2024","article-title":"A Novel Human Hepatocyte Cell Line to Study PNPLA3-Associated Steatotic Liver Disease","volume":"329","author":"Huang","year":"2025","journal-title":"Am. J. Physiol.-Gastrointest. Liver Physiol."},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"e16186","DOI":"10.1111\/liv.16186","article-title":"Targeting PNPLA3 to Treat MASH and MASH Related Fibrosis and Cirrhosis","volume":"45","author":"Tesz","year":"2025","journal-title":"Liver Int."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"101450","DOI":"10.1016\/j.jhepr.2025.101450","article-title":"PNPLA3 I148M Variant Links to Adverse Metabolic Traits in MASLD during Fasting and Feeding","volume":"7","author":"Jegodzinski","year":"2025","journal-title":"JHEP Rep."},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1159\/000539371","article-title":"EASL-EASD-EASO Clinical Practice Guidelines on the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)","volume":"17","author":"Tacke","year":"2024","journal-title":"Obes. Facts"},{"key":"ref_107","doi-asserted-by":"crossref","unstructured":"Kanda, T., Sasaki-Tanaka, R., Abe, H., Kimura, N., Yoshida, T., Hayashi, K., Sakamaki, A., Yokoo, T., Kamimura, H., and Tsuchiya, A. (2025). Polygenic Risk Score for Metabolic Dysfunction-Associated Steatotic Liver Disease and Steatohepatitis: A Narrative Review. Int. J. Mol. Sci., 26.","DOI":"10.3390\/ijms26115164"},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"739","DOI":"10.1194\/jlr.M046607","article-title":"PNPLA3 Mediates Hepatocyte Triacylglycerol Remodeling","volume":"55","author":"Ruhanen","year":"2014","journal-title":"J. Lipid Res."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"871","DOI":"10.1016\/j.jhep.2024.10.048","article-title":"PNPLA3(148M) Is a Gain-of-Function Mutation That Promotes Hepatic Steatosis by Inhibiting ATGL-Mediated Triglyceride Hydrolysis","volume":"82","author":"Wang","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_110","doi-asserted-by":"crossref","unstructured":"Bulutoglu, B., Rey-Bed\u00f3n, C., Mert, S., Tian, L., Jang, Y.-Y., Yarmush, M.L., and Usta, O.B. (2020). A Comparison of Hepato-Cellular in Vitro Platforms to Study CYP3A4 Induction. PLoS ONE, 15.","DOI":"10.1371\/journal.pone.0229106"},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1007\/s10565-015-9306-9","article-title":"Evaluation of CYP3A4 Inhibition and Hepatotoxicity Using DMSO-Treated Human Hepatoma HuH-7 Cells","volume":"31","author":"Liu","year":"2015","journal-title":"Cell Biol. Toxicol."},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"15848","DOI":"10.1038\/s41598-019-52174-w","article-title":"Rapid Maturation of the Hepatic Cell Line Huh7 via CDK Inhibition for PXR Dependent CYP450 Metabolism and Induction","volume":"9","author":"Bulutoglu","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1007\/s00204-011-0733-y","article-title":"Comparative Analysis of Phase I and II Enzyme Activities in 5 Hepatic Cell Lines Identifies Huh-7 and HCC-T Cells with the Highest Potential to Study Drug Metabolism","volume":"86","author":"Lin","year":"2012","journal-title":"Arch. Toxicol."},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1093\/cvr\/cvae121","article-title":"A Suite of Genome-Engineered Hepatic Cells Provides Novel Insights into the Spatiotemporal Metabolism of Apolipoprotein B and Apolipoprotein B\u2013Containing Lipoprotein Secretion","volume":"120","author":"Meurs","year":"2024","journal-title":"Cardiovasc. Res."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"e14482","DOI":"10.14814\/phy2.14482","article-title":"Modifying Nutritional Substrates Induces Macrovesicular Lipid Droplet Accumulation and Metabolic Alterations in a Cellular Model of Hepatic Steatosis","volume":"8","author":"Gunn","year":"2020","journal-title":"Physiol. Rep."},{"key":"ref_116","doi-asserted-by":"crossref","unstructured":"Perrin-Cocon, L., Kundlacz, C., Jacquemin, C., Hanoulle, X., Aublin-Gex, A., Figl, M., Manteca, J., Andr\u00e9, P., Vidalain, P.-O., and Lotteau, V. (2022). Domain 2 of Hepatitis C Virus Protein NS5A Activates Glucokinase and Induces Lipogenesis in Hepatocytes. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23020919"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1038\/s42003-021-01749-3","article-title":"A Hexokinase Isoenzyme Switch in Human Liver Cancer Cells Promotes Lipogenesis and Enhances Innate Immunity","volume":"4","author":"Vidalain","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"499","DOI":"10.1007\/s10616-020-00398-4","article-title":"Characterization of Huh7 Cells after the Induction of Insulin Resistance and Post-Treatment with Metformin","volume":"72","year":"2020","journal-title":"Cytotechnology"},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"726","DOI":"10.5152\/tjg.2024.23601","article-title":"In Vitro Simulated Ketogenic Diet Inhibits the Proliferation and Migration of Liver Cancer Cells by Reducing Insulin Production and Down-Regulating FOXC2 Expression","volume":"35","author":"Ma","year":"2024","journal-title":"Turk. J. Gastroenterol."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/j.mito.2021.10.001","article-title":"In Vitro Models of Insulin Resistance: Mitochondrial Coupling Is Differently Affected in Liver and Muscle Cells","volume":"61","author":"Pavlovic","year":"2021","journal-title":"Mitochondrion"},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"Palasantzas, V.E.J.M., Struik, D., Bos, T., Withoff, S., Fu, J., Jonker, J.W., and Hoogerland, J.A. (2026). Assessing Nutraceuticals for Hepatic Steatosis: A Standardized In Vitro Approach. Nutrients, 18.","DOI":"10.3390\/nu18030388"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"14333","DOI":"10.1038\/s41598-022-18174-z","article-title":"A Novel Differentiated HuH-7 Cell Model to Examine Bile Acid Metabolism, Transport and Cholestatic Hepatotoxicity","volume":"12","author":"Saran","year":"2022","journal-title":"Sci. Rep."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Chavez-Tapia, N.C., Rosso, N., and Tiribelli, C. (2012). Effect of Intracellular Lipid Accumulation in a New Model of Non-Alcoholic Fatty Liver Disease. BMC Gastroenterol., 12.","DOI":"10.1186\/1471-230X-12-20"},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"838","DOI":"10.4254\/wjh.v8.i20.838","article-title":"Lipogenesis in Huh7 Cells Is Promoted by Increasing the Fructose: Glucose Molar Ratio","volume":"8","author":"Windemuller","year":"2016","journal-title":"World J. Hepatol."},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1023\/A:1007404028681","article-title":"Immortalized Human Hepatocytes as a Tool for the Study of Hepatocytic (de-)Differentiation","volume":"13","author":"Schippers","year":"1997","journal-title":"Cell Biol. Toxicol."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1128\/JVI.74.2.864-874.2000","article-title":"pRB-Dependent, J Domain-Independent Function of Simian Virus 40 Large T Antigen in Override of P53 Growth Suppression","volume":"74","author":"Gjoerup","year":"2000","journal-title":"J. Virol."},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"102","DOI":"10.3109\/13813455.2012.683442","article-title":"The Human Hepatocyte Cell Lines IHH and HepaRG: Models to Study Glucose, Lipid and Lipoprotein Metabolism","volume":"118","author":"Samanez","year":"2012","journal-title":"Arch. Physiol. Biochem."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1007\/s00418-016-1532-6","article-title":"Peroxisomal Abnormalities in the Immortalized Human Hepatocyte (IHH) Cell Line","volume":"147","author":"Klouwer","year":"2017","journal-title":"Histochem. Cell Biol."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1186\/s13073-022-01071-5","article-title":"Acetyl-CoA Metabolism Drives Epigenome Change and Contributes to Carcinogenesis Risk in Fatty Liver Disease","volume":"14","author":"Assante","year":"2022","journal-title":"Genome Med."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1038\/s42255-022-00620-x","article-title":"BMP4 and Gremlin 1 Regulate Hepatic Cell Senescence during Clinical Progression of NAFLD\/NASH","volume":"4","author":"Baboota","year":"2022","journal-title":"Nat. Metab."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"100669","DOI":"10.1016\/j.jlr.2024.100669","article-title":"GCKIII Kinases Control Hepatocellular Lipid Homeostasis via Shared Mode of Action","volume":"65","author":"Cansby","year":"2024","journal-title":"J. Lipid Res."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/labinvest.3700590","article-title":"Microarray Analyses and Molecular Profiling of Steatosis Induction in Immortalized Human Hepatocytes","volume":"87","author":"Vinciguerra","year":"2007","journal-title":"Lab. Investig."},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"101630","DOI":"10.1016\/j.jcmgh.2025.101630","article-title":"Loss of Bile Salt Export Pump (Bsep\/Abcb11) Ameliorates Toxin-Induced Hepatic Fibrosis via Suppression of Hepatocellular Jun Amino-Terminal Kinase Signaling and Hepatic Stellate Cell Activation","volume":"20","author":"Fuchs","year":"2025","journal-title":"Cell. Mol. Gastroenterol. Hepatol."},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"1177","DOI":"10.1007\/s11357-022-00713-1","article-title":"Human Centenarian\u2013Associated SIRT6 Mutants Modulate Hepatocyte Metabolism and Collagen Deposition in Multilineage Hepatic 3D Spheroids","volume":"45","author":"Frohlich","year":"2022","journal-title":"GeroScience"},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/s00018-023-04827-3","article-title":"Loss of Functional Peroxisomes Leads to Increased Mitochondrial Biogenesis and Reduced Autophagy That Preserve Mitochondrial Function","volume":"80","author":"Chi","year":"2023","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"e70390","DOI":"10.1111\/jcmm.70390","article-title":"Standard Protocols for Characterising Primary and In Vitro-Generated Human Hepatocytes","volume":"29","author":"Heydari","year":"2025","journal-title":"J. Cell. Mol. Med."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"1800347","DOI":"10.1002\/biot.201800347","article-title":"3D Primary Hepatocyte Culture Systems for Analyses of Liver Diseases, Drug Metabolism, and Toxicity: Emerging Culture Paradigms and Applications","volume":"14","author":"Lauschke","year":"2019","journal-title":"Biotechnol. J."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"25187","DOI":"10.1038\/srep25187","article-title":"Characterization of Primary Human Hepatocyte Spheroids as a Model System for Drug-Induced Liver Injury, Liver Function and Disease","volume":"6","author":"Bell","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1007\/s44164-025-00097-4","article-title":"High-Yield Isolation of Primary Human Hepatocytes from Small Liver Samples","volume":"4","author":"Guy","year":"2025","journal-title":"In Vitro Models"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"1678","DOI":"10.1073\/pnas.1919035117","article-title":"Expansion, in Vivo\u2013Ex Vivo Cycling, and Genetic Manipulation of Primary Human Hepatocytes","volume":"117","author":"Michailidis","year":"2020","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"4138","DOI":"10.1021\/acsptsci.5c00554","article-title":"Comparative Analysis of Species-Specific Hepatocyte Function and Drug Effects in a Liver Microphysiological System PhysioMimix LC12 and 96-Well Plates","volume":"8","author":"Negi","year":"2025","journal-title":"ACS Pharmacol. Transl. Sci."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"E1063","DOI":"10.1152\/ajpendo.00125.2011","article-title":"PNPLA3 Is Regulated by Glucose in Human Hepatocytes, and Its I148M Mutant Slows down Triglyceride Hydrolysis","volume":"302","author":"Caron","year":"2012","journal-title":"Am. J. Physiol. Endocrinol. Metab."},{"key":"ref_143","doi-asserted-by":"crossref","unstructured":"Sukowati, C.H., Rosso, N., Pascut, D., Anfuso, B., Torre, G., Francalanci, P., Croc\u00e8, L.S., and Tiribelli, C. (2012). Gene and Functional Up-Regulation of the BCRP\/ABCG2 Transporter in Hepatocellular Carcinoma. BMC Gastroenterol., 12.","DOI":"10.1186\/1471-230X-12-160"},{"key":"ref_144","doi-asserted-by":"crossref","first-page":"101558","DOI":"10.1016\/j.molmet.2022.101558","article-title":"Chronic Hyperinsulinemia Promotes Human Hepatocyte Senescence","volume":"64","author":"Baboota","year":"2022","journal-title":"Mol. Metab."},{"key":"ref_145","doi-asserted-by":"crossref","unstructured":"Bankoglu, E.E., Tschopp, O., Schmitt, J., Burkard, P., Jahn, D., Geier, A., and Stopper, H. (2016). Role of PTEN in Oxidative Stress and DNA Damage in the Liver of Whole-Body Pten Haplodeficient Mice. PLoS ONE, 11.","DOI":"10.1371\/journal.pone.0166956"},{"key":"ref_146","doi-asserted-by":"crossref","first-page":"529","DOI":"10.1046\/j.1525-1594.2001.025007529.x","article-title":"Novel Strategies for Immortalization of Human Hepatocytes","volume":"25","author":"Cascio","year":"2001","journal-title":"Artif. Organs"},{"key":"ref_147","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1177\/030098589803500601","article-title":"The Cell Cycle: A Review","volume":"35","author":"Schafer","year":"1998","journal-title":"Vet. Pathol."},{"key":"ref_148","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1007\/978-1-4939-2074-7_4","article-title":"Immortalized Human Hepatic Cell Lines for in Vitro Testing and Research Purposes","volume":"Volume 1250","author":"Ramboer","year":"2015","journal-title":"Protocols in In Vitro Hepatocyte Research"},{"key":"ref_149","doi-asserted-by":"crossref","unstructured":"de Bardet, J.C., Cardentey, C.R., Gonz\u00e1lez, B.L., Patrone, D., Mulet, I.L., Siniscalco, D., and Robinson-Agramonte, M.d.l.A. (2023). Cell Immortalization: In Vivo Molecular Bases and In Vitro Techniques for Obtention. BioTech, 12.","DOI":"10.3390\/biotech12010014"},{"key":"ref_150","doi-asserted-by":"crossref","first-page":"101929","DOI":"10.1016\/j.isci.2020.101929","article-title":"Combinatorial Expression of Cell Cycle Regulators Is More Suitable for Immortalization than Oncogenic Methods in Dermal Papilla Cells","volume":"24","author":"Fukuda","year":"2020","journal-title":"iScience"},{"key":"ref_151","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1006\/bbrc.1999.0389","article-title":"The Influence of SV40 Immortalization of Human Fibroblasts on P53-Dependent Radiation Responses","volume":"257","author":"Kohli","year":"1999","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_152","doi-asserted-by":"crossref","unstructured":"Bonnet, L., Alexandersson, I., Baboota, R.K., Kroon, T., Oscarsson, J., Smith, U., and Boucher, J. (2022). Cellular Senescence in Hepatocytes Contributes to Metabolic Disturbances in NASH. Front. Endocrinol., 13.","DOI":"10.3389\/fendo.2022.957616"},{"key":"ref_153","doi-asserted-by":"crossref","first-page":"101353","DOI":"10.1016\/j.molmet.2021.101353","article-title":"STE20-Type Kinase TAOK3 Regulates Hepatic Lipid Partitioning","volume":"54","author":"Xia","year":"2021","journal-title":"Mol. Metab."},{"key":"ref_154","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/hep4.1702","article-title":"STE20-Type Protein Kinase MST4 Controls NAFLD Progression by Regulating Lipid Droplet Dynamics and Metabolic Stress in Hepatocytes","volume":"5","author":"Caputo","year":"2021","journal-title":"Hepatol. Commun."},{"key":"ref_155","doi-asserted-by":"crossref","first-page":"100238","DOI":"10.1016\/j.jlr.2022.100238","article-title":"Inhibition of MAP4K4 Signaling Initiates Metabolic Reprogramming to Protect Hepatocytes from Lipotoxic Damage","volume":"63","author":"Anand","year":"2022","journal-title":"J. Lipid Res."},{"key":"ref_156","doi-asserted-by":"crossref","first-page":"E578","DOI":"10.1152\/ajpendo.00365.2018","article-title":"Lipid and Glucose Metabolism in Hepatocyte Cell Lines and Primary Mouse Hepatocytes: A Comprehensive Resource for in Vitro Studies of Hepatic Metabolism","volume":"316","author":"Nagarajan","year":"2019","journal-title":"Am. J. Physiol.-Endocrinol. Metab."},{"key":"ref_157","doi-asserted-by":"crossref","first-page":"7173","DOI":"10.1038\/s41467-024-51078-2","article-title":"Adipose Tissue Macrophage Infiltration and Hepatocyte Stress Increase GDF-15 throughout Development of Obesity to MASH","volume":"15","author":"Sermikli","year":"2024","journal-title":"Nat. Commun."},{"key":"ref_158","doi-asserted-by":"crossref","first-page":"102090","DOI":"10.1016\/j.molmet.2024.102090","article-title":"Intrahepatic Levels of Microbiome-Derived Hippurate Associates with Improved Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"92","author":"Deslande","year":"2024","journal-title":"Mol. Metab."},{"key":"ref_159","doi-asserted-by":"crossref","first-page":"4074","DOI":"10.3748\/wjg.v25.i30.4074","article-title":"Role of Hepatocyte Nuclear Factor 4-Alpha in Gastrointestinal and Liver Diseases","volume":"25","author":"Yeh","year":"2019","journal-title":"World J. Gastroenterol."},{"key":"ref_160","doi-asserted-by":"crossref","unstructured":"Scheffschick, A., Babel, J., Sperling, S., Nerusch, J., Herzog, N., Seehofer, D., and Damm, G. (2022). Primary-like Human Hepatocytes Genetically Engineered to Obtain Proliferation Competence as a Capable Application for Energy Metabolism Experiments in In Vitro Oncologic Liver Models. Biology, 11.","DOI":"10.3390\/biology11081195"},{"key":"ref_161","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1124\/dmd.116.074369","article-title":"Transcriptional, Functional, and Mechanistic Comparisons of Stem Cell\u2013Derived Hepatocytes, HepaRG Cells, and Three-Dimensional Human Hepatocyte Spheroids as Predictive In Vitro Systems for Drug-Induced Liver Injury","volume":"45","author":"Bell","year":"2017","journal-title":"Drug Metab. Dispos."},{"key":"ref_162","doi-asserted-by":"crossref","unstructured":"Varmazyad, M., Gavlock, D.C., Castiglione, M.W., DeBiasio, R., LaRocca, G., Reese, C., Vernetti, L.A., Schurdak, M., Stern, A.M., and Taylor, D.L. (2026). Road Map for Primary Hepatocyte Qualification in Human Liver Organ Models. BMC Methods, 3.","DOI":"10.1186\/s44330-026-00058-7"},{"key":"ref_163","doi-asserted-by":"crossref","first-page":"112377","DOI":"10.1016\/j.biopha.2021.112377","article-title":"CYP450 Drug Inducibility in NAFLD via an in Vitro Hepatic Model: Understanding Drug-Drug Interactions in the Fatty Liver","volume":"146","author":"Banik","year":"2022","journal-title":"Biomed. Pharmacother."},{"key":"ref_164","doi-asserted-by":"crossref","first-page":"101478","DOI":"10.1016\/j.dmpk.2025.101478","article-title":"In Vitro Liver Models for Toxicological Research","volume":"62","author":"Fukunaga","year":"2025","journal-title":"Drug Metab. Pharmacokinet."},{"key":"ref_165","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1007\/s43188-025-00289-w","article-title":"Advancing Hepatotoxicity Assessment: Current Advances and Future Directions","volume":"41","author":"Kim","year":"2025","journal-title":"Toxicol. Res."},{"key":"ref_166","doi-asserted-by":"crossref","first-page":"11585","DOI":"10.1038\/s41598-019-47737-w","article-title":"The TM6SF2 E167K Genetic Variant Induces Lipid Biosynthesis and Reduces Apolipoprotein B Secretion in Human Hepatic 3D Spheroids","volume":"9","author":"Prill","year":"2019","journal-title":"Sci. Rep."},{"key":"ref_167","doi-asserted-by":"crossref","first-page":"e193805","DOI":"10.1172\/jci.insight.193805","article-title":"PNPLA3-I148M Genetic Variant Rewires Lipid Metabolism to Drive Programmed Cell Death in Human Hepatocytes","volume":"10","author":"Florentino","year":"2025","journal-title":"JCI Insight"},{"key":"ref_168","doi-asserted-by":"crossref","unstructured":"Paolini, E., Meroni, M., Longo, M., Badiali, S., Maggioni, M., Fracanzani, A.L., and Dongiovanni, P. (2026). The I148M PNPLA3 Variant Forces Progressive Portal MASLD by Spatially Perturbing Metabolic Pathways Across Liver Zones. Int. J. Mol. Sci., 27.","DOI":"10.3390\/ijms27031601"},{"key":"ref_169","doi-asserted-by":"crossref","unstructured":"Seidemann, L., Rohm, C.M., Stilkerich, A., H\u00e4nsel, R., G\u00f6tz, C., Seehofer, D., and Damm, G. (2025). Human Hepatocytes in Experimental Steatosis: Influence of Donor Sex and Sex Hormones. Biomedicines, 13.","DOI":"10.3390\/biomedicines13112770"},{"key":"ref_170","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1093\/toxsci\/kfx289","article-title":"Comparison of Hepatic 2D Sandwich Cultures and 3D Spheroids for Long-Term Toxicity Applications: A Multicenter Study","volume":"162","author":"Bell","year":"2018","journal-title":"Toxicol. Sci."},{"key":"ref_171","doi-asserted-by":"crossref","first-page":"799","DOI":"10.1002\/hep.26414","article-title":"Proteome-Wide Analyses of Human Hepatocytes during Differentiation and Dedifferentiation","volume":"58","author":"Rowe","year":"2013","journal-title":"Hepatology"},{"key":"ref_172","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.bbrc.2023.04.054","article-title":"HepaSH Cells: Experimental Human Hepatocytes with Lesser Inter-Individual Variation and More Sustainable Availability than Primary Human Hepatocytes","volume":"663","author":"Uehara","year":"2023","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"ref_173","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1016\/j.jhep.2024.06.040","article-title":"Induction of Steatosis in Primary Human Hepatocytes Recapitulates Key Pathophysiological Aspects of Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"82","author":"Kwon","year":"2025","journal-title":"J. Hepatol."},{"key":"ref_174","doi-asserted-by":"crossref","first-page":"3380","DOI":"10.1038\/s41598-025-33332-9","article-title":"Expression and Function of CYP Enzymes and Hepatobiliary Transporters in an Improved Long-Term Sandwich Culture Hepatocyte Model","volume":"16","author":"Pacsuta","year":"2026","journal-title":"Sci. Rep."},{"key":"ref_175","doi-asserted-by":"crossref","unstructured":"Sharma, S., Mells, J.E., Fu, P.P., Saxena, N.K., and Anania, F.A. (2011). GLP-1 Analogs Reduce Hepatocyte Steatosis and Improve Survival by Enhancing the Unfolded Protein Response and Promoting Macroautophagy. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0025269"},{"key":"ref_176","first-page":"626","article-title":"Lipid Accumulation Impairs Adiponectin-Mediated Induction of Activin A by Increasing TGFbeta in Primary Human Hepatocytes","volume":"1811","author":"Wanninger","year":"2011","journal-title":"Biochim. Biophys. Acta BBA-Mol. Cell Biol. Lipids"},{"key":"ref_177","first-page":"675","article-title":"Hepatic Steatosis Causes Induction of the Chemokine RANTES in the Absence of Significant Hepatic Inflammation","volume":"3","author":"Kirovski","year":"2010","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_178","doi-asserted-by":"crossref","unstructured":"Mahli, A., Seitz, T., Beckr\u00f6ge, T., Freese, K., Thasler, W.E., Benkert, M., Dietrich, P., Weiskirchen, R., Bosserhoff, A., and Hellerbrand, C. (2019). Bone Morphogenetic Protein-8B Expression Is Induced in Steatotic Hepatocytes and Promotes Hepatic Steatosis and Inflammation In Vitro. Cells, 8.","DOI":"10.3390\/cells8050457"},{"key":"ref_179","doi-asserted-by":"crossref","unstructured":"Breher-Esch, S., Sahini, N., Trincone, A., Wallstab, C., and Borlak, J. (2018). Genomics of Lipid-Laden Human Hepatocyte Cultures Enables Drug Target Screening for the Treatment of Non-Alcoholic Fatty Liver Disease. BMC Med. Genom., 11.","DOI":"10.1186\/s12920-018-0438-7"},{"key":"ref_180","doi-asserted-by":"crossref","unstructured":"Murphy, W.A., Kyburz, S., Ho, H., Loop, M.S., Fallon, J.K., Tiley, J.B., Kralj, T., and Brouwer, K.L.R. (2026). Development of an in Vitro Metabolic Dysfunction-Associated Steatohepatitis Model to Investigate Altered Drug Metabolizing Enzymes, Transport Proteins, and Hepatobiliary Disposition. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1664808"},{"key":"ref_181","doi-asserted-by":"crossref","first-page":"15837","DOI":"10.1038\/s41598-023-42785-9","article-title":"Micropatterned Primary Hepatocyte Co-Culture (HEPATOPAC) for Fatty Liver Disease Modeling and Drug Screening","volume":"13","author":"Cottier","year":"2023","journal-title":"Sci. Rep."},{"key":"ref_182","doi-asserted-by":"crossref","first-page":"1068","DOI":"10.33594\/000000288","article-title":"Palmitate and Fructose Interact to Induce Human Hepatocytes to Produce Pro-Fibrotic Transcriptional Responses in Hepatic Stellate Cells Exposed to Conditioned Media","volume":"54","author":"Piras","year":"2020","journal-title":"Cell. Physiol. Biochem. Int. J. Exp. Cell. Physiol. Biochem. Pharmacol."},{"key":"ref_183","doi-asserted-by":"crossref","first-page":"14297","DOI":"10.1038\/s41598-018-32722-6","article-title":"Human Hepatic 3D Spheroids as a Model for Steatosis and Insulin Resistance","volume":"8","author":"Kozyra","year":"2018","journal-title":"Sci. Rep."},{"key":"ref_184","doi-asserted-by":"crossref","first-page":"22765","DOI":"10.1038\/s41598-021-01951-7","article-title":"A 3D Primary Human Cell-Based in Vitro Model of Non-Alcoholic Steatohepatitis for Efficacy Testing of Clinical Drug Candidates","volume":"11","author":"Kostadinova","year":"2021","journal-title":"Sci. Rep."},{"key":"ref_185","doi-asserted-by":"crossref","first-page":"204","DOI":"10.3748\/wjg.v23.i2.204","article-title":"Three-Dimensional Perfused Human in Vitro Model of Non-Alcoholic Fatty Liver Disease","volume":"23","author":"Kostrzewski","year":"2017","journal-title":"World J. Gastroenterol."},{"key":"ref_186","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1002\/hep4.1450","article-title":"A Microphysiological System for Studying Nonalcoholic Steatohepatitis","volume":"4","author":"Kostrzewski","year":"2019","journal-title":"Hepatol. Commun."},{"key":"ref_187","doi-asserted-by":"crossref","first-page":"1080","DOI":"10.1038\/s42003-021-02616-x","article-title":"Modelling Human Liver Fibrosis in the Context of Non-Alcoholic Steatohepatitis Using a Microphysiological System","volume":"4","author":"Kostrzewski","year":"2021","journal-title":"Commun. Biol."},{"key":"ref_188","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1038\/s42003-025-09484-9","article-title":"A Microphysiological Model of Human MASLD Reveals Paradoxical Response to Resmetirom","volume":"9","author":"Hellen","year":"2026","journal-title":"Commun. Biol."},{"key":"ref_189","doi-asserted-by":"crossref","first-page":"e90954","DOI":"10.1172\/jci.insight.90954","article-title":"Development of an in Vitro Human Liver System for Interrogating Nonalcoholic Steatohepatitis","volume":"1","author":"Feaver","year":"2016","journal-title":"JCI Insight"},{"key":"ref_190","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1002\/hep4.1647","article-title":"Human Nonalcoholic Steatohepatitis on a Chip","volume":"5","author":"Freag","year":"2020","journal-title":"Hepatol. Commun."},{"key":"ref_191","doi-asserted-by":"crossref","first-page":"78","DOI":"10.1186\/1476-511X-13-78","article-title":"Linoleate Appears to Protect against Palmitate-Induced Inflammation in Huh7 Cells","volume":"13","author":"Maruyama","year":"2014","journal-title":"Lipids Health Dis."},{"key":"ref_192","doi-asserted-by":"crossref","unstructured":"Zhou, T., Zhou, Y., C\u00f6mert, C., Zhou, X.-Y., Lin, L., Bolund, L., Palmfeldt, J., Luo, Y., Bross, P., and Tong, G. (2026). Energy Metabolism Alteration and Gene Expression Reprogramming in a Cell Model of High Fat Load Non-Alcoholic Fatty Liver Disease. BMC Gastroenterol., 26.","DOI":"10.1186\/s12876-026-04658-z"},{"key":"ref_193","doi-asserted-by":"crossref","first-page":"0181","DOI":"10.34133\/bmef.0181","article-title":"Three-Dimensional Dynamic Cell Models for Metabolic Dysfunction-Associated Steatotic Liver Disease Progression","volume":"6","author":"Huang","year":"2025","journal-title":"BME Front."},{"key":"ref_194","doi-asserted-by":"crossref","first-page":"e00337","DOI":"10.1002\/adbi.202500337","article-title":"Primary Human Tissue Models for Metabolic Dysfunction-Associated Liver Disease\u2014Toward Streamlining Drug Discovery with Patient-Derived Assays","volume":"9","author":"Youhanna","year":"2025","journal-title":"Adv. Biol."},{"key":"ref_195","doi-asserted-by":"crossref","first-page":"1","DOI":"10.4161\/spmg.19885","article-title":"Cell Lines","volume":"2","author":"Kaur","year":"2012","journal-title":"Spermatogenesis"},{"key":"ref_196","doi-asserted-by":"crossref","first-page":"e17","DOI":"10.12771\/emj.2024.e17","article-title":"Sex Differences in Metabolic Dysfunction-Associated Steatotic Liver Disease: A Narrative Review","volume":"47","author":"Joo","year":"2024","journal-title":"Ewha Med. J."},{"key":"ref_197","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1016\/j.molmed.2024.05.013","article-title":"Sexual Dimorphism of Metabolic Dysfunction-Associated Steatotic Liver Disease","volume":"30","author":"Cherubini","year":"2024","journal-title":"Trends Mol. Med."},{"key":"ref_198","first-page":"17455057251376883","article-title":"Relationship between MASLD and Women\u2019s Health: A Review","volume":"21","author":"Jancova","year":"2025","journal-title":"Womens Health"},{"key":"ref_199","doi-asserted-by":"crossref","unstructured":"Milani, I., Chinucci, M., Leonetti, F., and Capoccia, D. (2025). MASLD: Prevalence, Mechanisms, and Sex-Based Therapies in Postmenopausal Women. Biomedicines, 13.","DOI":"10.3390\/biomedicines13040855"},{"key":"ref_200","doi-asserted-by":"crossref","unstructured":"Yang, L., Meng, Y., Shi, Y., Fang, H., and Zhang, L. (2023). Maternal Hepatic Immunology during Pregnancy. Front. Immunol., 14.","DOI":"10.3389\/fimmu.2023.1220323"}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4453\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,18]],"date-time":"2026-05-18T14:48:17Z","timestamp":1779115697000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/27\/10\/4453"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,15]]},"references-count":200,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2026,5]]}},"alternative-id":["ijms27104453"],"URL":"https:\/\/doi.org\/10.3390\/ijms27104453","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,15]]}}}